Mad Breakout to $65? Subtle Climb to $60? Quiet Retrace to $53?Oh Novanta. So many possibilities for such a great company. Please forgive the maddening amount of clustered lines. The primary trend line is massive and seemingly unstoppable for a reason. Even though it's gone parabolic, its story is rock solid and almost sexy with everything they have a hand in.
As a leader in medical and advanced, industrial markets, Novanta went through a period of optimization several years ago, is currently in organic growth mode and is accelerating its scale from now until 2020 in order to DOUBLE their annual revenue. Oh, and as of their last public statement, they're still on track to do so. Quality products, leadership and personnel (over 375 engineers), coupled with proprietary technologies and over 400 patents, Novanta maintains a stoic and disciplined M&A schedule in order to maintain its edge and continue to innovate by divesting around 9% of revenue in R&D. The crossover between their sectors is astounding. Organic growth, momentum, acquisitions, a great M&A pipeline and leadership positions across key medical and industrial markets are providing, as Matthijs Glastra said, "...a solid foundation for sustainable, profitable growth." If you want a laser, robotics and high level medical play, this is it.
Hold Novanta long term. Short term, if you're looking to just trade and not invest, there's been some massive momentum up from the previously, consistent levels held all of April. Based on how the stock has bounced off its bottom trend line, it was a good period of accumulation leading up to another spurt of gains towards the $58+ level. If it should shoot past this and hit what could easily be $65 (based off the previous $15+ jumps) sell immediately, because everyone else obviously did, twice.
A retrace back to $53 off this momentum isn't bad and will surely hold or prep for the bounce back up to the $60 range outlined above.
Robotics
Hi-Tech Medical+Robotics Play w/ $10 Stable, Transition RangeWith brand recognition and consistent sales in place, Mazor has stated that 2018 will be a transition year for them, not growth. Therefore, expect the company to aim for stability as it continues to spread its products. Per the last call: "2018 is expected to be a year of transition and our performance is expected to be driven primarily by increased revenues from the expanding installed base. Long-term, we would anticipate the installed base to expand considerably during the length of the global distribution agreement. Over the next five years, the largest result is a cumulative purchase of hundreds of Mazor X systems, which are expected to significantly accelerate procedure volume and growth."
Overall trend lines have been followed from 2017 into 2018 in a balanced manner. Some weakness definitely showed up after such a quick run-up into the -now- low part of this year's fib chart. A good period of accumulation presented itself before another push higher in January gave it momentum (along with everything else in the market). February hit, but the stock did not tumble horribly. It had one more push higher that went way beyond what anyone, anywhere was expecting. Forums were happily confused. As such, a LOT of profit taking took place and rightfully so after all the volatility that had been in play. Regardless, the company's fundamentals have not changed and the stock is now back to its previous, stable 2018 levels.
This is an excellent range to start a small position, as I expect the stock to continue trading back up close to $70 again with positive market momentum. Anything around the $56 level, where the stock has successfully bounced off of, is great for accumulation. A great company with an excellent product, vision and fundamentals makes holding this for stability within its range (and with opportunities for breakouts with ANY good news) a great pick for 2018. Technical trading within its $10 range ($58-68) is great for those who can time the market.
--Additional Backstory--
Mazor is a hi-tech, medical robotics company that specializes in creating systems for assistance during spinal surgery. Everyone knows that surgery is an expensive process and back surgery is extremely costly, difficult and more common than we'd care to imagine. The two systems that Mazor has developed and begun selling (in conjunction with Medtronic) are state of the art and well known within their field. While 2017 was quiet at first, the company began to grow in spurts with a huge push, in part from Medtronic, near the end of the year.
Hair Jump inThe shares of the corporation went up by 22.85% during the previous month. So far this year, the stock had gone up by 8.7%. With these types of results to display analysts, are more optimistic than before! Analyzing the last five market sessions, the stock was able to report 15.47% gains.Clarus Ventures LLC bought a new stake in shares of Restoration Robotics during the fourth quarter.HAIR has been the topic of several other reports and Roth Capital set a $7.50 price objective on shares of Restoration Robotics with a BUY rating in a recent research note.
TRXC BottomedOBV decline but price flat, retails stopped selling, short positions should stop out and rebound imminent for next catalyst.
ROBO ETF D1 LONGThe robotics/automation industry has at least 10 years of leg room for breakout growth.
$ROBO ETF provides maximum exposure at the nascent stage of growth.
Long for years.